



Representative Legal Matters

Mai Phan Zymaris

- Advised Astellas on its Research Collaboration and License Agreement with Elpiscience for novel bispecific macrophage engagers, including up to USD 37 million in upfront and option fees and potentially more than USD 1.7 billion in future development, regulatory, and commercial milestones.
- Represented a multinational pharmaceutical company in its commercialization agreement with an American healthcare company for a biologic as part of its broader plans to expand its foothold in the US market.

Prior to joining the Firm, Mai advised on the following matters:

- USD 1.5 billion+ exclusive license agreement between CSPC Pharmaceutical Group Limited and Elevation Oncology, Inc. to supply, develop and commercialize SYSA1801, a clinical stage antibody drug conjugate (ADC) targeting Claudin18.2, in all global territories outside Greater China.
- USD 700 million+ exclusive license agreement between CSPC Pharmaceutical Group Limited and Corbus Pharmaceutical Holdings to supply, develop and commercialize SYS6002, a clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the U.S., Australia, Canada, and varied European countries.
- Represented ACEA Therapeutics in an exclusive license agreement with Sorrento Therapeutics to develop and commercialize Abivertinib, a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).
- Represented ACEA Therapeutics in USD 488 million merger and acquisition transaction by their licensee, Sorrento Therapeutics.
- Represented Kindred Biosciences in an exclusive license agreement with Elanco Animal Health Incorporated to globally develop and commercialize KIND-030, a monoclonal antibody targeting canine parvovirus (CPV).
- Represented Kindred Biosciences, Inc. in USD 440 million acquisition transaction by their licensee, Elanco US, Inc.
- Represented Sanuwave Health in a license and marketing agreement with Celularity Inc. to commercialize BIOVANCE® Human Amniotic Membrane Allograft and Interfyl® Human Connective Tissue Matrix.
- Represented MyChem, a privately held provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets, in connection with its ≈ USD 240 million sale to Maravai (NASDAQ: MRVI).



- Advised LIVEKINDLY Collective on the commercial and intellectual property aspects of its establishment, together with RCL Foods, of a plant-based joint venture, LIVEKINDLY Collective Africa.
- Represented Special New Fruit Licensing (SNFL) in its acquisition of International Fruit Genetics (IFG).
- Represented The Foundation for Food & Agriculture Research on matters related to grant award agreements and private and public partnerships to advance food and agriculture research.
- Represented Sequite Genomics, a company that focuses on developing Next-Generation Sequencing (NGS) technology, in connection with its sale to Fapon Biotech.
- Represented Arbutus Biopharma in its Clinical Collaboration Agreement with Assembly Biosciences to evaluate the combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with chronic Hepatitis B virus infection.
- Represented Alexion Pharmaceuticals, Inc. in its USD 930 million acquisition by public company Achillion Pharmaceuticals, Inc.
- USD 1.7 billion research collaboration and licensing agreement between client Dicerna Pharmaceuticals, Inc. and Roche to develop and commercialize DCR-HBVS for the treatment of chronic Hepatitis B Virus (HBV) infection.
- USD 1 billion strategic collaboration between client LG Chem Ltd. and Cue Biopharma to develop and commercialize of Immuno-STAT™ Biologics in oncology.
- Represented OpenDeal dba Republic in various rounds worth of USD 200 million of equity financing.
- Represented OpenInvest, a leading financial technology company that helps financial professionals customize and report on values-based investments, in its sale to J.P. Morgan.